Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

BACKGROUND: Virtually all metastatic patients with metastatic melanoma who progress after initial treatment with PD-1 or CTLA-4 directed antibodies will die of their disease. Salvage options are urgently needed. It is theoretically attractive to combine immunotherapy with targeted agents in progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Samlowski, Wolfram, Adajar, Camille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573907/
https://www.ncbi.nlm.nih.gov/pubmed/34743688
http://dx.doi.org/10.1186/s12885-021-08906-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573907/
https://www.ncbi.nlm.nih.gov/pubmed/34743688
http://dx.doi.org/10.1186/s12885-021-08906-1

Ejemplares similares